Study Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple CAR T-cell therapy which combines CAR T cells against CLL-1 with CAR T cells targeting CD123 or CD33 in patients with relapsed and refractory AML. The study also aims to learn more about the function of CAR T cells and their persistency in AML patients.
Want to learn more about this trial?
Request More InfoInterventions
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cellsBIOLOGICAL
Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute | Shenzhen | Guangdong | China |